Scientists test safety of new cancer drug mix
NCT ID NCT06575933
Summary
This early-stage study aimed to understand how a new lung cancer drug candidate, calderasib, interacts with two common medications (midazolam and digoxin) in the body. Researchers gave healthy volunteers the new drug along with the other medicines to see if it changed how their bodies processed them. The goal was to gather safety data to inform future studies in cancer patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion ( Site 0001)
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.